1
|
Shi J, Yin X, Xu R, Wang Y, Jin L, Gao W. Clinical application of contrast enhanced ultrasound to diagnose benign prostatic hyperplasia. Diagn Pathol 2014; 9:133. [PMID: 24986664 PMCID: PMC4108000 DOI: 10.1186/1746-1596-9-133] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/24/2014] [Accepted: 06/05/2014] [Indexed: 11/23/2022] Open
Abstract
Abstract Virtual Slides The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/4852383312229155
Collapse
Affiliation(s)
- Jingfang Shi
- Department of Ultrasound, Jiading Center Hospital, Shanghai 201800, China.
| | | | | | | | | | | |
Collapse
|
2
|
Koseoglu RD, Erdemir F, Parlaktas BS, Filiz NO, Uluocak N, Etikan I. Effect of Chronic Prostatitis on Angiogenic Activity and Serum Prostate Specific Antigen Level in Benign Prostatic Hyperplasia. Kaohsiung J Med Sci 2007; 23:387-94. [PMID: 17666305 DOI: 10.1016/s0257-5655(07)70002-0] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022] Open
Abstract
The aim of this study was to evaluate the effect of chronic inflammatory pathology on the angiogenic activity in benign prostatic hyperplasia (BPH). Besides the presence of a relationship between serum prostate specific antigen (PSA) values and microvessel density (mvd), the intensity and extent (widespread or focal) of tissue PSA expression was also examined. The distribution of 30 cases according to the diagnosis groups was as follows: group 1, nine cases with prostatic adenocarcinoma; group 2, 10 cases with BPH and chronic prostatitis; group 3, 11 cases with BPH. The biopsy materials obtained by tru-cut biopsy (five cases) and transurethral resection (25 cases) were evaluated retrospectively. The evaluation of angiogenesis was made by CD34 immune marker, while the analysis of immunohistochemical tissue PSA expression was verified by PSA immune marker. Serum PSA levels and other clinical parameters were obtained from the clinical files of the patients. The mean age of the patients was 68 +/- 3 years (range, 48-83 years). The difference between the mean mvd values of the groups was statistically significant (chi2 = 10.492, p = 0.005). Group 1 showed higher mean mvd value than the other two groups. Although group 2 showed higher mean mvd value than group 3, the difference was not statistically significant (p = 0.863). There was no correlation between the mean mvd and serum PSA levels in any group. The intensity of PSA expression in prostate specimens was different in all groups. Maximum cases in group 3 showed high tissue PSA expression (chi2 = 12.442, p = 0.014). In group 1, there was a significant relationship between the intensity of PSA expression and the mean mvd (U = 1, p = 0.032). In group 2, a statistically significant correlation was noted between the mean serum PSA levels and the widespread occurrence of PSA expression (U = 0, p = 0.017). In the present study, we determined that chronic prostatitis had no effect on mvd in BPH cases. The correlation between tissue PSA expression and mvd was contradictory to the reports in the literature. Analyses in larger series are needed to prove the presence of a probable effect of chronic prostatitis on angiogenesis.
Collapse
Affiliation(s)
- Resit Dogan Koseoglu
- Department of Pathology, Gaziosmanpasa University School of Medicine, Tokat, Turkey
| | | | | | | | | | | |
Collapse
|
3
|
Titus MA, Gregory CW, Ford OH, Schell MJ, Maygarden SJ, Mohler JL. Steroid 5α-Reductase Isozymes I and II in Recurrent Prostate Cancer. Clin Cancer Res 2005; 11:4365-71. [PMID: 15958619 DOI: 10.1158/1078-0432.ccr-04-0738] [Citation(s) in RCA: 134] [Impact Index Per Article: 7.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
PURPOSE Prostate cancer recurs during androgen deprivation therapy despite reduced circulating androgens. We showed that recurrent prostate cancer tissue has testosterone levels similar to androgen-stimulated benign prostate, whereas dihydrotestosterone levels were reduced 82% to 1.45 nmol/L, sufficient for androgen receptor activation. The altered testosterone/dihydrotestosterone ratio in recurrent prostate cancer suggests loss of 5alpha-reducing capability. The aim of this study was to characterize steroid 5alpha-reductase isozymes I (S5alphaRI) and II (S5alphaRII) in prostate tissues. EXPERIMENTAL DESIGN A tissue microarray was constructed from 22 recurrent prostate cancer specimens and matched pairs of androgen-stimulated benign prostate and androgen-stimulated prostate cancer from 23 radical prostatectomy specimens. Immunoblots were constructed from eight recurrent prostate cancers, eight androgen-stimulated benign prostate, and eight androgen-stimulated prostate cancer specimens. Isozyme expression was examined in microarray sections and immunoblots using S5alphaRI and S5alphaRII polyclonal antibodies. Isozyme activities were measured in 12 recurrent prostate cancer, 12 androgen-stimulated benign prostate, and 12 androgen-stimulated prostate cancer specimens. RESULTS Nuclear immunostaining exhibited higher S5alphaRI expression than S5alphaRII in recurrent prostate cancer, androgen-stimulated benign prostate, and androgen-stimulated prostate cancers (P < 0.0001); mean expression was 125, 150, and 115 for S5alphaRI versus 10, 29, and 37 for S5alphaRII, respectively. Cytoplasmic immunostaining was moderate and similar for both isozymes in the three tissue types (P > 0.05). Immunoblots confirmed immunohistochemistry; S5alphaRI was expressed in recurrent prostate cancer specimens and S5alphaRII was not detected. The activity of S5alphaRI (114.4 pmol/mg epithelial protein/minute) was 3.7-fold higher than S5alphaRII (30.7 pmol/mg epithelial protein/minute) in recurrent prostate cancer specimens. CONCLUSIONS Expression levels and isozyme activity shifts from S5alphaRII toward S5alphaRI in recurrent prostate cancer. Dual inhibition of S5alphaRI and S5alphaRII should reduce dihydrotestosterone biosynthesis and may prevent or delay growth of recurrent prostate cancer.
Collapse
Affiliation(s)
- Mark A Titus
- Department of Pathology and Laboratory Medicine, Surgery, University of North Carolina School of Medicine, Chapel Hill, North Carolina 27599-7295, USA.
| | | | | | | | | | | |
Collapse
|
4
|
Kleespies A, Bruns CJ, Jauch KW. Clinical significance of VEGF-A, -C and -D expression in esophageal malignancies. Oncol Res Treat 2005; 28:281-8. [PMID: 15867486 DOI: 10.1159/000085198] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Abstract
Vascular endothelial growth factors (VEGF)-A, -C and -D are members of the proangiogenic VEGF family of glycoproteins. VEGF-A is known to be the most important angiogenic factor under physiological and pathological conditions, while VEGF-C and VEGF-D are implicated in the development and sprouting of lymphatic vessels, so called lymphangiogenesis. Local tumor progression, lymph node metastases and hematogenous tumor spread are important prognostic factors for esophageal carcinoma (EC), one of the most lethal malignancies throughout the world. We found solid evidence in the literature that VEGF expression contributes to tumor angiogenesis, tumor progression and lymph node metastasis in esophageal squamous cell carcinoma (SCC), and many authors could show a prognostic value for VEGF-assessment. In adenocarcinoma (AC) of the esophagus angiogenic properties are acquired in early stages, particularly in precancerous lesions like Barrett's dysplasia. However, VEGF expression fails to give prognostic information in AC of the esophagus. VEGF-C and -D were detected in SCC and dysplastic lesions, but not in normal mucosa of the esophagus. VEGF-C expression might be associated with lymphatic tumor invasion, lymph node metastases and advanced disease in esophageal SCC and AC. Therapeutic interference with VEGF signaling may prove to be a promising way of anti-angiogenic co-treatment in esophageal carcinoma. However, concrete clinical data are still pending.
Collapse
Affiliation(s)
- Axel Kleespies
- Chirurgische Klinik und Poliklinik, Klinikum Grosshadern, Ludwig-Maximilians-Universität München, Germany.
| | | | | |
Collapse
|
5
|
Kleespies A, Guba M, Jauch KW, Bruns CJ. Vascular endothelial growth factor in esophageal cancer. J Surg Oncol 2004; 87:95-104. [PMID: 15282704 DOI: 10.1002/jso.20070] [Citation(s) in RCA: 111] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
Vascular endothelial growth factor (VEGF) plays a crucial role in angiogenesis of many solid malignancies. The influence of angiogenesis and VEGF expression on progression and recurrence of esophageal cancer has been investigated over the last years. This article reviews the prognostic significance of VEGF expression, microvessel density (MVD), and lymphangiogenic factors in squamous cell carcinoma (SCC), Barrett's dysplasia, and adenocarcinoma (AC) of the esophagus, their predictive value for treatment response to chemo-radiotherapy and new anti-angiogenic treatment strategies.
Collapse
Affiliation(s)
- Axel Kleespies
- Department of Surgery, Klinikum Grosshadern, Ludwig-Maximilian-University, Munich, Germany.
| | | | | | | |
Collapse
|
6
|
Ward WK, Wood MD, Casey HM, Quinn MJ, Federiuk IF. The effect of local subcutaneous delivery of vascular endothelial growth factor on the function of a chronically implanted amperometric glucose sensor. Diabetes Technol Ther 2004; 6:137-45. [PMID: 15117580 DOI: 10.1089/152091504773731320] [Citation(s) in RCA: 37] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
The foreign body capsule that forms around implanted devices such as glucose sensors is hypovascular and has limited permeability to glucose. Such a capsule may function better if well vascularized. We hypothesized that capsular vascularization achieved by local release of vascular endothelial growth factor (VEGF) would lead to enhanced function. Amperometric glucose sensor array disks, each with four indicating electrodes, were implanted into rats. Animals received local subcutaneous infusions of VEGF(165) via osmotic pumps at a location on the sensor face 2 mm from one of the electrodes ("near units"). "Intermediate" electrode units were 15 mm, and "distant" units were 22 mm, from the VEGF source. Every 2 weeks, a glucose infusion was given to assess sensor function by telemetry. Near units demonstrated a lower lag duration (delay after blood glucose) than intermediate and distant units. The mean absolute relative difference for near units was less than for distant units. The percentage of data pairs in the A region of the Clarke error grid of the near sensing units was greater than that of the distant units. Values for the functional measures for saline controls fell between near and distant VEGF values. Glucose sensor function was found to be more favorable in units immediately adjacent to the VEGF infusion port. The most likely cause for this finding is increased neovessel growth in the surrounding foreign body capsule. Slow release of angiogenic growth factors may be a potential method for chronically enhancing the function of a subcutaneously implanted biosensor.
Collapse
Affiliation(s)
- W Kenneth Ward
- Clinical Research and Technology Center, Legacy Health System, Portland, Oregon 97232,
| | | | | | | | | |
Collapse
|
7
|
Büchler P, Reber HA, Ullrich A, Shiroiki M, Roth M, Büchler MW, Lavey RS, Friess H, Hines OJ. Pancreatic cancer growth is inhibited by blockade of VEGF-RII. Surgery 2004; 134:772-82. [PMID: 14639356 DOI: 10.1016/s0039-6060(03)00296-4] [Citation(s) in RCA: 42] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
Abstract
BACKGROUND Angiogenesis is important in the development and progression of pancreatic cancer. Therefore antiangiogenic therapy targeting endothelial cells may represent a promising therapeutic option. The aim of the study was to evaluate antiangiogenic therapy as a potential therapeutic option in pancreatic cancer. METHODS Replication-deficient retroviruses encoding truncated VEGF-RII were used to block vascular endothelial growth factor (VEGF) signaling. Tumor growth of 3 pancreatic cancer cell lines was assayed in a nude mouse model in which each pancreatic cancer cell line was subcutaneously inoculated together with retrovirus-producing cells. Expression of VEGF was assayed by RT-PCR and by enzyme-linked immunosorbent assay. Oxygen tension in tumors was determined polarographically. RESULTS All 3 pancreatic cancer cell lines expressed VEGF mRNA, with the highest VEGF secretion seen in MIA PaCa-2 cells. In vivo therapeutic intervention through dominant negative inhibition of VEGF-RII significantly reduced the growth rate of subcutaneous tumors and inhibited tumor neoangiogenesis. Tumor oxygenation, however, was not altered in xenograft tumors treated with dominant negative retroviruses. CONCLUSION The ligand/receptor system consisting of VEGF and VEGF-RII seems to be of biologic significance in the pathogenesis of pancreatic cancer growth. Therefore therapeutic intervention in this angiogenic system by a retroviral-based gene transfer technology represents a rational and feasible new technique to inhibit tumor growth.
Collapse
Affiliation(s)
- Peter Büchler
- Department of Surgery, UCLA School of Medicine, University of California-Los Angeles, 10833 Le Conte, Los Angeles, CA 90095-6904, USA
| | | | | | | | | | | | | | | | | |
Collapse
|
8
|
Sun YX, Wang J, Shelburne CE, Lopatin DE, Chinnaiyan AM, Rubin MA, Pienta KJ, Taichman RS. Expression of CXCR4 and CXCL12 (SDF-1) in human prostate cancers (PCa) in vivo. J Cell Biochem 2003; 89:462-73. [PMID: 12761880 DOI: 10.1002/jcb.10522] [Citation(s) in RCA: 347] [Impact Index Per Article: 16.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Abstract
Human prostate cancers (PCa) express great variability in their ability to metastasize to bone. The identification of molecules associated with aggressive phenotypes will help to define PCa subsets and will ultimately lead to better treatment strategies. The chemokine stromal-derived factor-1 (SDF-1 or CXCL12) and its receptor CXCR4 are now known to modulate the migration and survival of an increasing array of normal and malignant cell types including breast, pancreatic cancers, glioblastomas, and others. The present investigation extends our previous investigations by determining the expression of CXCR4 and CXCL12 in humans using high-density tissue microarrays constructed from clinical samples obtained from a cohort of over 600 patients. These data demonstrate that CXCR4 protein expression is significantly elevated in localized and metastastic cancers. At the RNA level, human PCa tumors also express CXCR4 and message, but overall, they were not significantly different suggesting post-transcriptional regulation of the receptor plays a major role in regulating protein expression. Similar observations were made for CXCL12 message, but in this case more CXCL12 message was expressed by metastastic lesions as compared to normal tissues. PCa cell lines also express CXCL12 mRNA, and regulate mRNA expression in response to CXCL12 and secrete biologically active protein. Furthermore, neutralizing antibody to CXCL12 decreased the proliferation of bone homing LNCaP C4-2B and PC3 metastastic tumor cells. These investigations provide important new information pertaining to the molecular basis of how tumors may 'home' to bone, and the mechanisms that may account for their growth in selected end organs.
Collapse
Affiliation(s)
- Yan-Xi Sun
- Department of Periodontics, Prevention, Geriatrics, University of Michigan School of Dentistry, 1011 North University Ave., Ann Arbor, Michigan 48109-1078, USA
| | | | | | | | | | | | | | | |
Collapse
|
9
|
Eder JP, Supko JG, Clark JW, Puchalski TA, Garcia-Carbonero R, Ryan DP, Shulman LN, Proper J, Kirvan M, Rattner B, Connors S, Keogan MT, Janicek MJ, Fogler WE, Schnipper L, Kinchla N, Sidor C, Phillips E, Folkman J, Kufe DW. Phase I clinical trial of recombinant human endostatin administered as a short intravenous infusion repeated daily. J Clin Oncol 2002; 20:3772-84. [PMID: 12228197 DOI: 10.1200/jco.2002.02.082] [Citation(s) in RCA: 175] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022] Open
Abstract
PURPOSE To perform a phase I trial of recombinant human endostatin (rhEndostatin; EntreMed, Rockville, MD) given as a daily 20-minute intravenous (IV) injection in adult patients with refractory solid tumors. PATIENTS AND METHODS The daily dose was increased from 15 to 240 mg/m(2) by a factor of 100% in cohorts of three patients. In the absence of dose-limiting toxicity, uninterrupted treatment was continued until the tumor burden increased by more than 50% from baseline. Correlative studies included dynamic contrast-enhanced magnetic resonance imaging of tumor blood flow, urinary vascular endothelial growth factor and basic fibroblast growth factor levels, rhEndostatin serum pharmacokinetics, and monitoring of circulating antibodies to rhEndostatin. RESULTS There were no notable treatment related toxicities among 15 patients receiving a total of 50 monthly cycles of rhEndostatin. One patient with a pancreatic neuroendocrine tumor had a minor response and two patients showed disease stabilization. Linearity in the pharmacokinetics of rhEndostatin was indicated by dose-proportionate increases in the area under the curve for the first dose and the peak serum concentration at steady state. Daily systemic exposure to rhEndostatin in patients receiving 240 mg/m(2)/d was approximately 50% lower than that provided by the therapeutically optimal dose in preclinical studies. CONCLUSION rhEndostatin administered as a 20-minute daily IV injection at doses up to 240 mg/m(2) showed no significant toxicities. Evidence of clinical benefit was observed in three patients. Due to high variability between the peak and trough serum concentrations associated with the repeated short IV infusion schedule, daily serum drug levels only briefly exceeded concentrations necessary for in vitro antiangiogenic effects.
Collapse
Affiliation(s)
- Joseph P Eder
- Division of Adult Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
10
|
Decreased Suburethral Prostatic Microvessel Density In Finasteride Treated Prostates: A Possible Mechanism For Reduced Bleeding In Benign Prostatic Hyperplasia. J Urol 2002. [DOI: 10.1097/00005392-200204000-00034] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
11
|
Hochberg DA, Basillote JB, Armenakas NA, Vasovic L, Shevchuk M, Pareek G, Fracchia JA. Decreased Suburethral Prostatic Microvessel Density In Finasteride Treated Prostates: A Possible Mechanism For Reduced Bleeding In Benign Prostatic Hyperplasia. J Urol 2002. [DOI: 10.1016/s0022-5347(05)65188-9] [Citation(s) in RCA: 41] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
Affiliation(s)
- David A. Hochberg
- From the Sections of Urology and Pathology, Lenox Hill Hospital, New York, New York
| | - Jay B. Basillote
- From the Sections of Urology and Pathology, Lenox Hill Hospital, New York, New York
| | - Noel A. Armenakas
- From the Sections of Urology and Pathology, Lenox Hill Hospital, New York, New York
| | - Liliana Vasovic
- From the Sections of Urology and Pathology, Lenox Hill Hospital, New York, New York
| | - Maria Shevchuk
- From the Sections of Urology and Pathology, Lenox Hill Hospital, New York, New York
| | - Gyan Pareek
- From the Sections of Urology and Pathology, Lenox Hill Hospital, New York, New York
| | - John A. Fracchia
- From the Sections of Urology and Pathology, Lenox Hill Hospital, New York, New York
| |
Collapse
|
12
|
Doll JA, Reiher FK, Crawford SE, Pins MR, Campbell SC, Bouck NP. Thrombospondin-1, vascular endothelial growth factor and fibroblast growth factor-2 are key functional regulators of angiogenesis in the prostate. Prostate 2001; 49:293-305. [PMID: 11746276 DOI: 10.1002/pros.10025] [Citation(s) in RCA: 107] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
BACKGROUND Prostate cells secrete many molecules capable of regulating angiogenesis; however, which of these actually function as essential regulators of neovascularization is not yet clear. METHODS Functional angiogenic mediators secreted by normal and diseased prostate cells were identified using an in vitro angiogenesis assay. These factors were quantified by immunoblot or ELISA and localized in tissue by immunohistochemistry. RESULTS Normal prostate epithelial cell secretions were anti-angiogenic due to inhibitory thrombospondin-1 (TSP-1) whereas this inhibitor was decreased in the pro-angiogenic secretions derived from benign prostatic hyperplasia (BPH) and cancer cells. This pro-angiogenic activity depended primarily on fibroblast growth factor-2 (FGF-2) and/or vascular endothelial growth factor (VEGF) whose secretion was increased. Immunolocalization studies confirmed that the changes detected in vitro also occurred in vivo. CONCLUSIONS During disease progression in the prostate, production of TSP-1, the major inhibitor, is down-regulated while that of stimulatory FGF-2 and/or VEGF rise, leading to the induction of the new vessels necessary to support tumor growth.
Collapse
Affiliation(s)
- J A Doll
- Department of Microbiology-Immunology, Northwestern University Medical School, Chicago, IL 60611, USA.
| | | | | | | | | | | |
Collapse
|
13
|
D'Angio CT, Ambati J, Phelps DL. Do urinary levels of vascular endothelial growth factor predict proliferative retinopathy? Curr Eye Res 2001; 22:90-4. [PMID: 11402385 DOI: 10.1076/ceyr.22.2.90.5526] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
Abstract
PURPOSE Vascular endothelial growth factor (VEGF) is elevated in the vitreous of patients with proliferative retinopathies (PR). Angiogenic factors like VEGF are elevated in the urine of subjects with cancers, including those distant from the genitourinary tract. We hypothesized that local increases in VEGF in the vitreous would be reflected in the urine of subjects with PR. METHODS Urine samples were collected from adults with absent, mild, or severe (requiring laser photocoagulation) PR. VEGF was measured by enzyme linked immunosorbent assay. RESULTS Of 42 subjects, 16 had no PR and 26 had PR (8 mild, 18 severe). Thirty subjects had diabetes mellitus; 24 of these had PR. Subjects with PR were older than controls. Subjects with PR tended to have higher urinary VEGF (median 123 pg/ml Cr, range 3--1738) than controls without PR (median 93 pg/ml Cr, range 2--200) (p = 0.08). None of 16 controls, but 11/15 subjects with PR had >200 mg VEGF/mg Cr (p = 0.003), yielding high specificity (100%), but poor sensitivity (42%) of elevated urinary VEGF for PR. Urinary VEGF was also modestly correlated with urinary protein excretion (r(2 ) = 0.23). Correction of VEGF values for urinary protein abrogated any correlation with PR. CONCLUSIONS Urinary levels of VEGF are associated with PR, but this relationship may be caused by concurrent renal diseases that result in proteinuria and/or renal VEGF production. The insensitivity of the association may preclude its use in screening to avoid eye examinations.
Collapse
Affiliation(s)
- C T D'Angio
- Strong Children's Research Center, Department of Pediatrics, University of Rochester School of Medicine and Dentistry, Rochester, New York 14642, USA.
| | | | | |
Collapse
|
14
|
Strohmeyer D, Rössing C, Bauerfeind A, Kaufmann O, Schlechte H, Bartsch G, Loening S. Vascular endothelial growth factor and its correlation with angiogenesis and p53 expression in prostate cancer. Prostate 2000; 45:216-24. [PMID: 11074523 DOI: 10.1002/1097-0045(20001101)45:3<216::aid-pros3>3.0.co;2-c] [Citation(s) in RCA: 83] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Abstract
BACKGROUND Previously it was demonstrated that in prostate tumors, angiogenesis measured as microvessel density (MVD) is associated with tumor stage as well as WHO grade and is an independent predictor of clinical outcome. Vascular endothelial growth factor (VEGF) is a major inducer of angiogenesis. There is some evidence that P53 mutations cause overexpression of VEGF. We studied VEGF expression, p53 overexpression, and P53 mutations in prostate cancer (PCA) to investigate the role of VEGF as an angiogenic marker and the possible deregulation of VEGF as a result of P53 mutations in PCA. METHODS Immunohistochemical staining with a polyclonal VEGF antibody was performed in 55 paraffin-embedded PCA, in which MVD had previously been determined, as well as in 5 prostatic adenomas (PA) and 20 adjacent normal prostate tissues. In addition, 37 PCA and 5 PAs were examined for p53 expression by immunohistochemistry. Temperature gradient gel electrophoresis (TGGE) was performed in 13 of these PCA to screen for P53 mutations. VEGF expression, p53 expression, and mutations were then correlated with tumor stage, grade, MVD, and clinical outcome. RESULTS While PA and normal prostate tissue generally showed no or only low VEGF expression, there was a significant increase in VEGF expression with tumor stage, grade, and MVD in PCA. During clinical follow-up (mean, 31.9 months), 9 of 55 patients had tumor progression. Significant differences in VEGF expression were found between patients with tumor progression and those without (P = 0.0004). Of the 37 PCA evaluated for p53 expression, 12 exhibited p53 overexpression. TGGE revealed P53 mutations in 3 of 13 PCA. However, there was no correlation between VEGF expression, p53 overexpression, and P53 mutation, respectively. CONCLUSIONS VEGF seems to be an important, clinically relevant inducer of angiogenesis in PCA. VEGF expression was shown to correlate positively with tumor stage, grade, MVD, and clinical outcome. However, regulation of VEGF in PCA appears to be independent of p53 expression.
Collapse
Affiliation(s)
- D Strohmeyer
- Department of Urology, University of Innsbruck, Austria.
| | | | | | | | | | | | | |
Collapse
|
15
|
PAVLOVICH CHRISTIANP, KRÄLING BIRGITM, STEWART ROBERTJ, CHEN XIAOHONG, BOCHNER BERNARDH, LUSTER ANDREWD, POPPAS DIXP, O’DONNELL MICHAELA. BCG-INDUCED URINARY CYTOKINES INHIBIT MICROVASCULAR ENDOTHELIAL CELL PROLIFERATION. J Urol 2000. [DOI: 10.1016/s0022-5347(05)67620-3] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
Affiliation(s)
- CHRISTIAN P. PAVLOVICH
- From the James Buchanan Brady Foundation, Department of Urology, The New York Hospital - Cornell Medical Center, New York, New York, the Surgical Research Laboratory, Department of Surgery, Children’s Hospital - Harvard Medical School, Boston, Massachusetts, the Division of Urology, Department of Surgery, The Toronto Hospital, University of Toronto, Toronto, Canada, the Division of Urology, Department of Surgery, Beth Israel Deaconess Medical Center - Harvard Medical School, Boston, Massachusetts,
| | - BIRGIT M. KRÄLING
- From the James Buchanan Brady Foundation, Department of Urology, The New York Hospital - Cornell Medical Center, New York, New York, the Surgical Research Laboratory, Department of Surgery, Children’s Hospital - Harvard Medical School, Boston, Massachusetts, the Division of Urology, Department of Surgery, The Toronto Hospital, University of Toronto, Toronto, Canada, the Division of Urology, Department of Surgery, Beth Israel Deaconess Medical Center - Harvard Medical School, Boston, Massachusetts,
| | - ROBERT J. STEWART
- From the James Buchanan Brady Foundation, Department of Urology, The New York Hospital - Cornell Medical Center, New York, New York, the Surgical Research Laboratory, Department of Surgery, Children’s Hospital - Harvard Medical School, Boston, Massachusetts, the Division of Urology, Department of Surgery, The Toronto Hospital, University of Toronto, Toronto, Canada, the Division of Urology, Department of Surgery, Beth Israel Deaconess Medical Center - Harvard Medical School, Boston, Massachusetts,
| | - XIAOHONG CHEN
- From the James Buchanan Brady Foundation, Department of Urology, The New York Hospital - Cornell Medical Center, New York, New York, the Surgical Research Laboratory, Department of Surgery, Children’s Hospital - Harvard Medical School, Boston, Massachusetts, the Division of Urology, Department of Surgery, The Toronto Hospital, University of Toronto, Toronto, Canada, the Division of Urology, Department of Surgery, Beth Israel Deaconess Medical Center - Harvard Medical School, Boston, Massachusetts,
| | - BERNARD H. BOCHNER
- From the James Buchanan Brady Foundation, Department of Urology, The New York Hospital - Cornell Medical Center, New York, New York, the Surgical Research Laboratory, Department of Surgery, Children’s Hospital - Harvard Medical School, Boston, Massachusetts, the Division of Urology, Department of Surgery, The Toronto Hospital, University of Toronto, Toronto, Canada, the Division of Urology, Department of Surgery, Beth Israel Deaconess Medical Center - Harvard Medical School, Boston, Massachusetts,
| | - ANDREW D. LUSTER
- From the James Buchanan Brady Foundation, Department of Urology, The New York Hospital - Cornell Medical Center, New York, New York, the Surgical Research Laboratory, Department of Surgery, Children’s Hospital - Harvard Medical School, Boston, Massachusetts, the Division of Urology, Department of Surgery, The Toronto Hospital, University of Toronto, Toronto, Canada, the Division of Urology, Department of Surgery, Beth Israel Deaconess Medical Center - Harvard Medical School, Boston, Massachusetts,
| | - DIX P. POPPAS
- From the James Buchanan Brady Foundation, Department of Urology, The New York Hospital - Cornell Medical Center, New York, New York, the Surgical Research Laboratory, Department of Surgery, Children’s Hospital - Harvard Medical School, Boston, Massachusetts, the Division of Urology, Department of Surgery, The Toronto Hospital, University of Toronto, Toronto, Canada, the Division of Urology, Department of Surgery, Beth Israel Deaconess Medical Center - Harvard Medical School, Boston, Massachusetts,
| | - MICHAEL A. O’DONNELL
- From the James Buchanan Brady Foundation, Department of Urology, The New York Hospital - Cornell Medical Center, New York, New York, the Surgical Research Laboratory, Department of Surgery, Children’s Hospital - Harvard Medical School, Boston, Massachusetts, the Division of Urology, Department of Surgery, The Toronto Hospital, University of Toronto, Toronto, Canada, the Division of Urology, Department of Surgery, Beth Israel Deaconess Medical Center - Harvard Medical School, Boston, Massachusetts,
| |
Collapse
|
16
|
Honkanen EO, Teppo AM, Grönhagen-Riska C. Decreased urinary excretion of vascular endothelial growth factor in idiopathic membranous glomerulonephritis. Kidney Int 2000; 57:2343-9. [PMID: 10844604 DOI: 10.1046/j.1523-1755.2000.00094.x] [Citation(s) in RCA: 43] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
BACKGROUND Membranous glomerulonephritis (MGN) has, for unknown reasons, an unpredictable and highly variable clinical course. Vascular endothelial growth factor (VEGF) enhances endothelial cell proliferation, angiogenesis, microvascular permeability, and monocyte chemotaxis, and it activates proteinases. In normal kidneys, it is predominantly expressed by glomerular podocytes, where its physiological function and role in development of renal diseases are obscure. This study was designed to evaluate the urinary excretion of VEGF in MGN compared with several other glomerular disease and to asses its relationships to the clinical activity of MGN. METHODS Urinary VEGF was studied during renal biopsy using a sandwich enzyme immunoassay from 30 patients with idiopathic MGN, 8 with minimal change glomerulonephritis, 10 with focal segmental glomerulosclerosis (FSGS), 8 with necrotizing glomerulonephritis associated with systemic vasculitis, and 12 with diabetic nephropathy. In addition, 33 healthy controls were examined. Fifteen patients with MGN were re-evaluated 12 months later, and the evolution of proteinuria was compared with changes in urinary VEGF excretion. RESULTS In healthy control subjects, urinary VEGF excretion was 68 +/- 10 (95% CI, 49 to 88) ng/mmol creatinine (UCr). In MGN, the excretion was decreased to 16 +/- 3 (CI, 10 to 23) ng/mmol crea (P < 0.0001, ANOVA), whereas in minimal change glomerulonephritis and diabetic nephropathy, it was unchanged [55 +/- 14 (CI, 24 to 86) and 101 +/- 25 (CI, 45 to 156) ng/mmol UCr, respectively, P = NS]. In vasculitis and FSGS patients, the excretion was higher than normal [184 +/- 68 (CI, 24 to 344), P = 0.01, and 160 +/- 29 (CI 95 to 226), P = 0.002 ng/mmol UCr, respectively]. The excretion did not correlate with serum VEGF, renal function, or proteinuria. In the follow-up of 15 patients, improving MGN (decreasing proteinuria) was associated with increasing VEGF excretion, while persistent disease (no change or increase of proteinuria) was associated with constantly low urinary VEGF excretion. The change in urinary protein excretion over one year correlated inversely with the change in urinary VEGF (r = -0.57, P = 0.026). CONCLUSIONS MGN is associated with decreased urinary VEGF compared with normal subjects, which is in contrast with other proteinuric diseases. Moreover, decreasing clinical activity (proteinuria) is accompanied by increasing VEGF excretion. Urinary VEGF may serve as an indicator of activity of MGN.
Collapse
Affiliation(s)
- E O Honkanen
- Division of Nephrology, Department of Medicine, Helsinki University Hospital, Helsinki, Finland. eero.honkanen2fimnet.fi
| | | | | |
Collapse
|
17
|
BCG-INDUCED URINARY CYTOKINES INHIBIT MICROVASCULAR ENDOTHELIAL CELL PROLIFERATION. J Urol 2000. [DOI: 10.1097/00005392-200006000-00112] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
18
|
Jones A, Fujiyama C. Angiogenesis in urological malignancy: prognostic indicator and therapeutic target. BJU Int 1999; 83:535-55; quiz 555-6. [PMID: 10210606 DOI: 10.1046/j.1464-410x.1999.00018.x] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Affiliation(s)
- A Jones
- Department of Urology, Churchill Hospital, Oxford, UK
| | | |
Collapse
|
19
|
Abstract
BACKGROUND The separate structural and functional activities of the prostatic stroma were only recently discovered and are still poorly understood. METHODS This review summarizes recent literature on the structure, and on the angiogenic, contractile, proliferative, and secretory activities mediated by the prostatic stroma and its agents. RESULTS The stroma undergirds the acinar epithelium through its fibromuscular substance. Neovascularization of its hypoxic cells, a process driven by cytokines, especially vascular endothelial growth factor, provides fuel for glycolytic empowerment of smooth muscle contraction, growth, and secretion. Signals from the stromal complement of cholinergic and adrenergic fibers, modulated by also-elaborated nitric oxide, provide tight regulation of uroflow. Apparently, autonomic control is independent of that of the powerful endothelin, secreted by the epithelium. Superimposed on these intrinsic elements of prostatic stromal control are the effects of steroid hormones and their effectors. CONCLUSIONS The illumination of the stroma's role in prostatic physiology, coupled with advances in knowledge of its pharmacology, should aid in our understanding, management, and prevention of prostatic disease.
Collapse
Affiliation(s)
- W E Farnsworth
- Department of Urology, Northwestern University Medical School, Bloomingdale, Illinois 60108, USA.
| |
Collapse
|